Immutep S.A. and Lonza Inc. Sign Agreement for Cell Line Selection, Cell Banking and Process Development of ImmuFact(R) IMP321
4/10/2012 11:23:20 AM
More...
|
Immutep S.A. and GlaxoSmithKline (GSK) Sign Licence Agreement for IMP731, a Novel Therapeutic Antibody for the Treatment of Autoimmune Diseases
1/6/2011 11:09:35 AM
More...
|
Immutep S.A. Announces Final Results in Phase I/II Chemoimmunotherapy Trial in Metastatic Breast Cancer
9/7/2010 1:54:45 PM
More...
|
Immutep S.A. Announces Oral Presentation At American Society of Clinical Oncology Annual Meeting Of IMP321 Final Results In Phase I/II Chemoimmunotherapy Trial
5/19/2010 10:59:14 AM
More...
|
Immutep S.A. Announces Final Results In Phase I/II Chemoimmunotherapy Trial In Breast Cancer
1/4/2010 10:52:45 AM
More...
|
Immutep S.A. Announces New Interim Results In Phase I/II Chemoimmunotherapy Trial In Breast Cancer
10/6/2009 2:05:45 PM
More...
|
Immutep S.A. Announces Final Results In Advanced Renal Cell Carcinoma
9/29/2009 1:20:24 PM
More...
|
Immutep S.A. Announces Start of Clinical Trial in Pancreatic Cancer
4/15/2009 11:44:11 AM
More...
|
Immutep S.A. Announces Positive Interim Results in Phase I/II Chemoimmunotherapy Trial in Breast Cancer
1/5/2009 8:05:25 AM
More...
|
Immutep S.A. Reports that LAG-3 Enhances Activity of a Cellular Cancer Immunotherapy in Preclinical Studies
6/25/2008 7:42:00 AM
More...
|
|